San Diego biotech Glycoregimmune raises $4.3 million for natural killer T cell-based therapy
San Diego biotech Glycoregimmune is working on a way to inhibit the natural killer T cells that exacerbate the inflammatory response and hepatic injury that stems from liver disease. Natural killer T cells are a sort of heterogenous variety of immune cell; the company says: NKT cells share properties of both NK and T cells and are a […]